Pharmacology of ATP-sensitive potassium channel (K(ATP)) openers in models of myocardial ischemia and reperfusion

Canadian Journal of Physiology and Pharmacology

Volumn 75, Issue 4, 1997, Pages 309-315

  Grover, Gary J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

ATP; ATP sensitive K+ channels; Heart; Myocardial ischemia; Reperfusion

Indexed keywords

APRIKALIM; CROMAKALIM; GLIBENCLAMIDE; N (4 CHLOROPHENYL) N' CYANO N'' (6 CYANO 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)GUANIDINE; PINACIDIL; POTASSIUM CHANNEL;

CHANNEL GATING; CONDITIONING; CONFERENCE PAPER; DRUG EFFECT; DRUG PROTEIN BINDING; ENERGY CONSERVATION; GUINEA PIG; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOPYRANS; CROMAKALIM; GUANIDINES; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIA, HEART; MODELS, CARDIOVASCULAR; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; NIACINAMIDE; NICORANDIL; PICOLINES; PINACIDIL; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PYRANS; PYRROLES; RATS;

EID: 0030786620     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/cjpp-75-4-309     Document Type: Conference Paper

References (49)

1. Aguilar-Bryan, L., Nichols, C.G, Wechsler, S.W., Clement, J.P., Boyd, A.E., Gonzalez, G., Herrera-Sosa, H., Nguy, K., Bryan, J., and Nelson, D.A. 1995. Cloning of the beta-cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science (Washington, D.C.), 268: 423-425.
2. Armstrong, S.C., Liu, G.S., Downey, J.M., and Ganote, C.E. 1995. Potassium channels and preconditioning of isolated rabbit cardiomyocytes: effects of glyburide and pinacidil. J. Mol. Cell. Cardiol. 27: 1765-1774.
3. Atwal, K. 1992. Modulation of potassium channels by organic molecules. Med. Res. Rev. 12: 569-591.
4. Atwal, K.S., Grover, G.J., Ahmed, S., Ferrara, F.N., Harper, T.W., Kim, K.S., Sleph, P.G., Dzwonczyk, S., Russell, A.D., Moreland, S., McCullough, J.R., and Normandin, D.E. 1993. Cardioselective anti-ischemic ATP-sensitive potassium channel openers. J. Med. Chem. 36: 3971-3974.
5. + channel opener aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J. Pharmacol. Exp. Ther. 259: 961-967.
6. Auchampach, J.A., Maruyama, M., Cavero, I., and Gross, G. 1992. Pharmacologic evidence for a role of ATP-dependent potassium channels in myocardial stunning. J. Pharmacol. Exp. Ther. 86: 311-319.
7. ATP-channel openers protect against increased cytosolic calcium during ischemia and reperfusion. J. Mol. Cell. Cardiol. 27: 1809-1817.
8. Cole, W.C., McPherson, C.D., and Sontag, D. 1991. ATP-regulated channels protect the myocardium against ischemia/reperfusion damage. Circ. Res. 69: 571-581.
9. D'Alonzo, A.J., Darbenzio, R.B., Parham, C.S., and Grover, G.J. 1992. Effects of intracoronary cromakalim on postischemic contractile function and action potential duration. Cardiovasc. Res. 26: 1046-1053.
10. + channels that are blocked by hypoglycemia-inducing sulfonylureas in insulin-secreting cells are activated by galanin, a hyperglycemia-inducing hormone. Proc. Natl. Acad. Sci. U.S.A. 85: 1312-1316.
11. Edwards, G., and Weston, A.H. 1993. The pharmacology of ATP-sensitive potassium channels. Annu. Rev. Pharmacol. Toxicol. 33: 597-637.
12. Galiñanes, M., Shattock, M.J., and Hearse, D.J. 1992. Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia. Cardiovasc. Res. 26: 1063-1068.
13. Garlid, K.D., Paucek, P., Yarov-Yarovoy, V., Sun, X., and Schindler, P.A. 1996. The mitochondrial KATP channel as a receptor for potassium channel openers. J. Biol. Chem. 271: 8796-8799.
14. Grover, G.J. 1994. Protective effects of ATP-sensitive potassium channel openers in experimental myocardial ischemia. J. Cardiovasc. Pharmacol. 24(Suppl. 4): S18-S27.
15. Grover, G.J., and Atwal, K.A. 1995. BMS-180448, a glyburide-reversible cardioprotective agent with minimal vasodilator activity. Cardiovasc. Drug Rev. 13: 123-136.
16. Grover, G.J., and Sleph, P.G. 1995. Protective effect of KATP openers in ischemic rat hearts treated with a potassium cardioplegic solution. J. Cardiovasc. Pharmacol. 265: 695-706.
17. Grover, G.J., Dzwonczyk, S., Parham, C.S., and Sleph, P.G. 1990a. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc. Drugs Ther. 4: 465-474.
18. Grover, G.J., Dzwonczyk, S., and Sleph, P.G. 1990b. Reduction of ischemic damage in isolated rat hearts by the potassium channel opener RP 52891. Eur. J. Pharmacol. 191: 11-19.
19. Grover, G.J., Newburger, J., Sleph, P.G., Dzwonczyk, S., Taylor, S.C., Ahmed, S.Z., and Atwal, K.S. 1991. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides. J. Pharmacol. Exp. Ther. 257: 156-162.
20. Grover, G.J., D'Alonzo, A.J., Hess, T., Sleph, P.G., and Darbenzio, R.B. 1995a. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening. Cardiovasc. Res. 30: 731-738.
21. Grover, G.J., D'Alonzo, A.J., Parham, C.S., and Darbenzio, R.B. 1995b. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration. J. Cardiovasc. Pharmacol. 26: 145-152.
22. Grover, G.J., Parham, C.S., Whigan, D.B., and Mitroka, J.G. 1996. BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs. J. Pharmacol. Exp. Ther. 276: 380-387.
23. + channels in cerebral ischemic preconditioning. Proc. Natl. Acad. Sci. U.S.A. 92: 4666-4670.
24. Imai, N., Liang, C., Stone, C.K., Sakamoto, S., and Hood, W.B. 1988. Comparative effects of nitroprusside and pinacidil on myocardial blood flow and infarct size in awake dogs with acute myocardial infarction. Circulation, 77: 705-711.
25. + channel in the mitochondrial inner membrane. Nature (London), 352: 244-247.
26. + loss and arrhythmias in rat hearts. Effect of glybenclamide, a sulfonylurea. Circ. Res. 66: 478-485.
27. Kitzen, J.M., McCallum, J.D., Harvey, C., Morin, M.E., Oshiro, G.T., and Colatsky, T.J. 1992. Potassium channel activators cromakalim and celikalim (WAY-120,491) fail to decrease myocardial infarct size in the anesthetized canine. Pharmacology, 45: 71-82.
28. McCullough, J.R., Normandin, D.E., Conder, M.L., Sleph, P.G., Dzwonczyk, S., and Grover, G.J. 1991. Specific block of the antiischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ. Res. 69: 949-958.
29. McPherson, C.D., Pierce, G.N., and Cole, W.C. 1993. Ischemic cardioprotection by ATP-sensitive potassium channels involves high-energy phosphate preservation. Am. J. Physiol. 265: H1809-H1818.
30. Mizumura, T., Nithipatikom, K., and Gross, G.J. 1995. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation, 92: 1236-1245.
31. + channels in cardiac muscle. Nature (London), 305: 147-148.
32. Ohta, H., Jinno, Y., Harada, K., Ogawa, N., Fukushima, K., and Nishikore, J. 1991. Cardioprotective effects of KRN2391 and nicorandil on ischemic dysfunction in perfused rat heart. Eur. J. Pharmacol. 204: 171-177.
33. ATP) channels in ischemic preconditioning (IPC) of pig skeletal muscles. FASEB J. 9: A422.
34. + channel from rat liver and beef heart mitochondria. J. Biol. Chem. 36: 26 062-26 069.
35. + channels. Science (Washington, D.C.), 268: 372-373.
36. + channel modulator aprikalim (RP 52891): improved cardioprotection in isolated ischemic rabbit hearts. Can. J. Physiol. Pharmacol. 72: 126-132.
37. Rohmann, S., Weygandt, H., Schelling, P., Kie Soei, L., Verdouw, P.D., and Lues, I. 1994. Involvement of ATP-sensitive potassium channels in preconditioning protection. Basic Res. Cardiol. 89: 563-576.
38. Sargent, C.A., Smith, M.A., Dzwonczyk, S., Sleph, P.G., and Grover, G.J. 1991. Effect of potassium channel blockade on the antiischemic actions of mechanistically diverse agents. J. Pharmacol. Exp. Ther. 259: 97-103.
39. Smallwood, J.K., and Steinberg, M.I. 1988. Cardiac electrophysiological effects of pinacidil and related pyridylcyanoguanidines: relationship to antihypertensive activity. J. Cardiovasc. Pharmacol. 12: 102-109.
40. Speechly-Dick, M.E., Grover, G.J., and Yellon, D.M. 1995. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent potassium channel? Studies of contractile function in an in vitro model. Circ. Res. 77: 1030-1038.
41. Spruce, A.E., Standen, N.B., and Stanfield, P.R. 1985. Voltage-dependent ATP-sensitive potassium channels of skeletal muscle membrane. Nature (London), 316: 736-738.
42. Tan, H.L., Mazon, P., Verberne, H.J., Sleeswijk, M.E., Coronel, R., Opthof, T., and Janse, M.J. 1993. Ischemic preconditioning delays ischemia induced cellular uncoupling in rabbit myocardium by activation of ATP-sensitive potassium channels. Cardiovasc. Res. 27: 644-651.
43. Thornton, J.D., Thornton, C.S., Sterling, K.L., and Downey, J.M. 1993. Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts. Circ. Res. 72: 44-49.
44. + channel blocker. Circulation, 90: 700-705.
45. Tosaki, A., and Hellegouarch, A. 1994. Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury. J. Am. Coll. Cardiol. 23: 496-497.
46. Treherne, J.M., and Ashford, M.L.J. 1991. The regional distribution of sulfphonylurea binding sites in rat brain. Neuroscience, 40: 523-531.
47. + loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ. Res. 69: 623-637.
48. ATP opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation, 89: 1769-1775.
49. Yao, Z., and Gross, G.J. 1994b. The ATP-dependent potassium channel: an endogenous cardioprotective mechanism. J. Cardiovasc. Pharmacol. 24(Suppl. 4): S28-S34.